Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Financing Activities (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash from Financing Activities over the past 9 years, most recently at $26.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 95.32% year-over-year to $26.0 million; the TTM value through Dec 2025 reached $40.6 million, down 96.0%, while the annual FY2025 figure was $40.6 million, 96.0% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $26.0 million at Crinetics Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $556.2 million in Q4 2024 and troughed at $57000.0 in Q1 2021.
  • A 5-year average of $91.1 million and a median of $14.1 million in 2021 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: soared 168823.71% in 2021 and later tumbled 99.93% in 2022.
  • Year by year, Cash from Financing Activities stood at $163.9 million in 2021, then tumbled by 99.93% to $115000.0 in 2022, then skyrocketed by 34870.43% to $40.2 million in 2023, then surged by 1283.12% to $556.2 million in 2024, then crashed by 95.32% to $26.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CRNX at $26.0 million in Q4 2025, $3.1 million in Q3 2025, and $7.1 million in Q2 2025.